Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter Ablation | 36 | 2025 | 315 | 8.250 |
Why?
|
| Tachycardia, Ventricular | 34 | 2024 | 254 | 7.340 |
Why?
|
| Pericardium | 10 | 2021 | 105 | 2.000 |
Why?
|
| Heart-Assist Devices | 7 | 2024 | 991 | 1.740 |
Why?
|
| Cardiomyopathies | 8 | 2021 | 513 | 1.570 |
Why?
|
| Atrial Fibrillation | 7 | 2024 | 732 | 1.110 |
Why?
|
| Heart Conduction System | 7 | 2017 | 161 | 0.950 |
Why?
|
| Photoacoustic Techniques | 1 | 2025 | 6 | 0.910 |
Why?
|
| Defibrillators, Implantable | 5 | 2021 | 213 | 0.880 |
Why?
|
| Arrhythmias, Cardiac | 6 | 2023 | 480 | 0.870 |
Why?
|
| Thorax | 1 | 2024 | 71 | 0.860 |
Why?
|
| Epicardial Mapping | 4 | 2015 | 10 | 0.750 |
Why?
|
| Tachycardia | 1 | 2021 | 71 | 0.680 |
Why?
|
| Pulmonary Veins | 2 | 2021 | 169 | 0.680 |
Why?
|
| Electric Countershock | 3 | 2020 | 79 | 0.680 |
Why?
|
| Heart | 1 | 2024 | 673 | 0.630 |
Why?
|
| Heart Failure | 5 | 2023 | 2306 | 0.620 |
Why?
|
| Ventricular Fibrillation | 1 | 2020 | 59 | 0.610 |
Why?
|
| Nanoparticles | 1 | 2022 | 293 | 0.590 |
Why?
|
| Prosthesis Implantation | 2 | 2021 | 145 | 0.580 |
Why?
|
| Endovascular Procedures | 2 | 2020 | 764 | 0.570 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 116 | 0.560 |
Why?
|
| Treatment Outcome | 24 | 2023 | 12911 | 0.540 |
Why?
|
| Electrocardiography | 11 | 2018 | 983 | 0.500 |
Why?
|
| Endocardium | 2 | 2014 | 47 | 0.490 |
Why?
|
| Recurrence | 15 | 2024 | 1476 | 0.470 |
Why?
|
| Heart Ventricles | 6 | 2023 | 768 | 0.450 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2015 | 251 | 0.420 |
Why?
|
| Cicatrix | 5 | 2022 | 125 | 0.410 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 547 | 0.410 |
Why?
|
| Ultrasonography | 4 | 2025 | 970 | 0.400 |
Why?
|
| Humans | 51 | 2024 | 131322 | 0.400 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2024 | 73 | 0.390 |
Why?
|
| Tachycardia, Supraventricular | 2 | 2017 | 110 | 0.390 |
Why?
|
| Palliative Care | 1 | 2016 | 443 | 0.380 |
Why?
|
| Heart Diseases | 2 | 2020 | 504 | 0.370 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 421 | 0.360 |
Why?
|
| Pleural Diseases | 1 | 2012 | 33 | 0.360 |
Why?
|
| Aged | 25 | 2024 | 21192 | 0.360 |
Why?
|
| Middle Aged | 29 | 2024 | 28780 | 0.350 |
Why?
|
| Fistula | 1 | 2012 | 52 | 0.350 |
Why?
|
| Swine | 2 | 2025 | 1186 | 0.350 |
Why?
|
| Heart Rate | 3 | 2020 | 579 | 0.330 |
Why?
|
| Survival Rate | 6 | 2023 | 2141 | 0.310 |
Why?
|
| Sinus Arrest, Cardiac | 1 | 2009 | 5 | 0.300 |
Why?
|
| Equipment Design | 3 | 2024 | 553 | 0.290 |
Why?
|
| Atrioventricular Node | 1 | 2009 | 19 | 0.290 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2009 | 32 | 0.290 |
Why?
|
| Anticoagulants | 1 | 2012 | 594 | 0.260 |
Why?
|
| Male | 33 | 2024 | 65065 | 0.240 |
Why?
|
| Ethanol | 2 | 2024 | 164 | 0.240 |
Why?
|
| Risk Factors | 6 | 2023 | 10940 | 0.240 |
Why?
|
| Female | 31 | 2024 | 70976 | 0.230 |
Why?
|
| Prosthesis Design | 2 | 2020 | 608 | 0.230 |
Why?
|
| Vacuum | 1 | 2024 | 12 | 0.220 |
Why?
|
| Retrospective Studies | 16 | 2024 | 17610 | 0.220 |
Why?
|
| Stroke | 1 | 2012 | 1049 | 0.210 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 88 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2024 | 1076 | 0.200 |
Why?
|
| Atrial Function | 2 | 2015 | 16 | 0.200 |
Why?
|
| Models, Animal | 1 | 2025 | 458 | 0.200 |
Why?
|
| Arteriovenous Fistula | 2 | 2016 | 55 | 0.190 |
Why?
|
| Mitral Valve | 1 | 2024 | 249 | 0.190 |
Why?
|
| Vagus Nerve Stimulation | 2 | 2015 | 62 | 0.190 |
Why?
|
| Patient Selection | 2 | 2016 | 723 | 0.180 |
Why?
|
| Sick Sinus Syndrome | 1 | 2021 | 16 | 0.180 |
Why?
|
| Atrioventricular Block | 1 | 2021 | 46 | 0.170 |
Why?
|
| Infection Control | 1 | 2021 | 161 | 0.160 |
Why?
|
| Pacemaker, Artificial | 3 | 2021 | 194 | 0.160 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 2297 | 0.160 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2011 | 132 | 0.150 |
Why?
|
| Action Potentials | 2 | 2020 | 473 | 0.150 |
Why?
|
| Incidence | 2 | 2017 | 3338 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2021 | 1170 | 0.150 |
Why?
|
| Comorbidity | 3 | 2021 | 1589 | 0.140 |
Why?
|
| Postoperative Complications | 3 | 2021 | 3110 | 0.140 |
Why?
|
| Vasoactive Intestinal Peptide | 2 | 2015 | 17 | 0.140 |
Why?
|
| Sympathectomy | 1 | 2017 | 8 | 0.130 |
Why?
|
| Myocardium | 1 | 2022 | 874 | 0.130 |
Why?
|
| Amiodarone | 1 | 2017 | 47 | 0.130 |
Why?
|
| Pericardial Effusion | 1 | 2017 | 72 | 0.130 |
Why?
|
| Body Surface Potential Mapping | 2 | 2015 | 17 | 0.120 |
Why?
|
| Brachiocephalic Trunk | 1 | 2016 | 35 | 0.120 |
Why?
|
| Animals | 6 | 2025 | 34327 | 0.120 |
Why?
|
| Monitoring, Intraoperative | 2 | 2014 | 130 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 168 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2017 | 816 | 0.110 |
Why?
|
| Compassionate Use Trials | 1 | 2015 | 17 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 273 | 0.110 |
Why?
|
| Magnetics | 1 | 2014 | 31 | 0.110 |
Why?
|
| Device Removal | 1 | 2016 | 222 | 0.110 |
Why?
|
| Atrial Appendage | 1 | 2015 | 76 | 0.100 |
Why?
|
| Suture Techniques | 1 | 2015 | 177 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2015 | 353 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1305 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1255 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2015 | 827 | 0.090 |
Why?
|
| Stroke Volume | 3 | 2021 | 528 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2018 | 3689 | 0.090 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2011 | 8 | 0.090 |
Why?
|
| Atrial Flutter | 1 | 2012 | 45 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 69 | 0.090 |
Why?
|
| Nerve Block | 1 | 2012 | 61 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 147 | 0.090 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 174 | 0.080 |
Why?
|
| Dogs | 4 | 2015 | 621 | 0.080 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2017 | 226 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2011 | 204 | 0.080 |
Why?
|
| Brugada Syndrome | 1 | 2009 | 13 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 1907 | 0.080 |
Why?
|
| Reflex | 1 | 2009 | 36 | 0.070 |
Why?
|
| Monitoring, Ambulatory | 1 | 2009 | 57 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2009 | 48 | 0.070 |
Why?
|
| Sodium Channels | 1 | 2009 | 99 | 0.070 |
Why?
|
| Texas | 1 | 2016 | 3610 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2007 | 28 | 0.070 |
Why?
|
| Myocardial Contraction | 1 | 2009 | 248 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 53 | 0.070 |
Why?
|
| Platelet Aggregation | 1 | 2007 | 104 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 463 | 0.070 |
Why?
|
| Caffeine | 1 | 2007 | 66 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 5264 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2112 | 0.060 |
Why?
|
| Fever | 1 | 2009 | 311 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2009 | 401 | 0.060 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2010 | 284 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 358 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 274 | 0.060 |
Why?
|
| Adult | 9 | 2018 | 31597 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 1343 | 0.050 |
Why?
|
| Refractory Period, Electrophysiological | 2 | 2015 | 8 | 0.050 |
Why?
|
| Atropine | 2 | 2015 | 30 | 0.050 |
Why?
|
| Electrodes, Implanted | 2 | 2017 | 174 | 0.050 |
Why?
|
| Gadolinium | 1 | 2022 | 111 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 6906 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2018 | 5115 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 6270 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 261 | 0.040 |
Why?
|
| Contrast Media | 1 | 2022 | 489 | 0.040 |
Why?
|
| Decision Trees | 1 | 2018 | 57 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2022 | 529 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 3086 | 0.030 |
Why?
|
| Italy | 1 | 2017 | 133 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2017 | 128 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 615 | 0.030 |
Why?
|
| United States | 3 | 2017 | 11761 | 0.030 |
Why?
|
| Global Health | 1 | 2021 | 632 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 120 | 0.030 |
Why?
|
| Muscarine | 1 | 2015 | 7 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 270 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2015 | 34 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1522 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 84 | 0.030 |
Why?
|
| Ligation | 1 | 2015 | 136 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 835 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1221 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2015 | 199 | 0.020 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2012 | 18 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 220 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 2869 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 89 | 0.020 |
Why?
|
| Arterial Pressure | 1 | 2012 | 131 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 4028 | 0.020 |
Why?
|
| Exercise Test | 1 | 2012 | 243 | 0.020 |
Why?
|
| Analgesia, Epidural | 1 | 2011 | 29 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 238 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 569 | 0.020 |
Why?
|
| Contraindications | 1 | 2010 | 77 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3447 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 310 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 326 | 0.020 |
Why?
|
| Torsion, Mechanical | 1 | 2009 | 6 | 0.020 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2009 | 41 | 0.020 |
Why?
|
| Rotation | 1 | 2009 | 40 | 0.020 |
Why?
|
| Japan | 1 | 2009 | 173 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2009 | 72 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 441 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 2009 | 126 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 1164 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 443 | 0.020 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2007 | 12 | 0.020 |
Why?
|
| Platelet Function Tests | 1 | 2007 | 38 | 0.020 |
Why?
|
| Hydrazones | 1 | 2007 | 18 | 0.020 |
Why?
|
| P-Selectin | 1 | 2007 | 69 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2007 | 239 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 330 | 0.020 |
Why?
|
| Piperazines | 1 | 2007 | 269 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 4938 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2009 | 929 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 1450 | 0.010 |
Why?
|
| Disease Progression | 1 | 2009 | 2205 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 3399 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 865 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 4686 | 0.010 |
Why?
|
| Child | 1 | 2011 | 26211 | 0.010 |
Why?
|